[HTML] mdpi.com

[HTML][HTML] Janus kinase inhibitors and coronavirus disease (COVID)-19: rationale, clinical evidence and safety issues

M Gatti, E Turrini, E Raschi, P Sestili, C Fimognari - Pharmaceuticals, 2021 - mdpi.com
We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …
被引用次数：41 相关文章

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues.

M Gatti, E Turrini, E Raschi, P Sestili… - Pharmaceuticals (Basel …, 2021 - europepmc.org
We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …

Janus Kinase inhibitors and coronavirus disease (COVID)-19: rationale, clinical evidence and safety issues.

M Gatti, E Turrini, E Raschi, P Sestili, C Fimognari - 2021 - cabidigitallibrary.org
We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

M Gatti, E Turrini, E Raschi, P Sestili… - …, 2021 - ora.uniurb.it
: We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

M Gatti, E Turrini, E Raschi, P Sestili… - …, 2021 - search.proquest.com
We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …
[PDF] semanticscholar.org

[PDF][PDF] Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale

M Gatti, E Turrini, E Raschi… - … and Safety Issues …, 2021 - pdfs.semanticscholar.org
We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …

Janus kinase inhibitors and coronavirus disease (Covid)‐19: Rationale, clinical evidence and safety issues

M Gatti, E Turrini, E Raschi, P Sestili… - …, 2021 - cris.unibo.it
We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID‐19), and a number of clinical trials have been or are …
[HTML] nih.gov

[HTML][HTML] Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

M Gatti, E Turrini, E Raschi, P Sestili… - …, 2021 - ncbi.nlm.nih.gov
We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

M Gatti, E Turrini, E Raschi… - Pharmaceuticals …, 2021 - pubmed.ncbi.nlm.nih.gov
We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …
[PDF] academia.edu

[PDF][PDF] Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale

M Gatti, E Turrini, E Raschi, P Sestili… - Clinical Evidence and …, 2021 - academia.edu
We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …